Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD ...

COPD often manifests as chronic bronchitis and emphysema, typically developing from prolonged exposure to irritants like ...

President and Chief Executive Officer of Regeneron. "Over one million patients around the globe are currently being treated with Dupixent, with more to come following the approvals for COPD in the ...

Regeneron recently secured approval for Dupixent in treating Chronic Obstructive Pulmonary Disease (COPD) in the European Union, with a pending approval decision in the United States expected in the ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition impacts millions globally, with a 2023 analysis by DelveInsight reporting ...